Author name: Machine User

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality.’ Retatrutide, an Eil Lilly drug yet to be approved by the FDA, boasting ‘…Phase 2 trial results […]

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials. Read More »

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day.

Hello all, It continues to be a fascinating, rapid and intense period of development in obesity and metabolic medicine. We learn something new virtually every week; we are very much looking forward to Obesity Week in Dallas, TX and the latest developments in evidence-based obesity science and treatments. In this Weekly Roundup, we have interesting articles including Novo

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day. Read More »

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

Hello all, I hope everyone is having a wonderful weekend. I am back home after an intense week on the road, capped by a terrific two days at the ASMBS Weekend conference in New Orleans (where twenty30 health is a Bronze-level Corporate Council Member). It was an outstanding opportunity to connect with old friends and

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds. Read More »

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

Hello Friends, Welcome to October. It has been an extraordinarily busy period here at twenty30 health; amongst many other activities and initiatives, yours’ truly has been hitting the conference circuit of late, and have had the opportunity to attend excellent events at DHNY in New York and Health Evolution in Nashville. I also had the

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition Read More »

record medical interest in obesity

Oprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based economic disruption.

Hello everyone, I hope you are well. We have some quite interesting news pieces this week, including reporting on Eli Lilly’s lawsuits against compounding pharmacies; record-setting interest in physicians applying to take the the American Board of Obesity Medicine (ABOM) exam; and, Oprah and a panel of obesity specialists diving into the GLP-1 topic. Also,

Oprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based economic disruption. Read More »

Over 70 companies in the obesity medications race

Over 70 companies in the obesity medications race; a new business model for weight management; obesity in youths as a public health emergency; a 40% reduction in blood cancers after bariatric surgery

Hello everyone, I hope you are enjoying this weekend, one where — at least in much of the US Northeast — the weather is feeling like the first crisp glimpses of autumn [though I note that, if you were exposed to Hurricane Lee, it may be wet and windy, and with the inconvenience of power

Over 70 companies in the obesity medications race; a new business model for weight management; obesity in youths as a public health emergency; a 40% reduction in blood cancers after bariatric surgery Read More »

Bariatric surgery

The future – or not – of bariatric surgery; access disparities in GLP-1 medications (and taking second jobs to pay for them); cost per avoided cardiovascular death; and, are bacteria the new Ozempic?

Hello everyone, Welcome to September; I hope you are well on this long Labour Day weekend in North America. [And I will note, Labour Day is celebrated in many more places around the world than just the US and Canada, though it is more commonly celebrated on May 1st and alternately or also known as

The future – or not – of bariatric surgery; access disparities in GLP-1 medications (and taking second jobs to pay for them); cost per avoided cardiovascular death; and, are bacteria the new Ozempic? Read More »

More on GLP-1s: adherence, complications, impact on desire; nextgen weight management; and, Lisa Marie Presley’s tragic death

Hello everyone, my very best to you this weekend, and I hope you are staying cool in this current heat wave in North America [if you are located here]. Hydrate, hydrate, hydrate! Overall, this has been a quiet mid-summer week, apart from any of you who celebrated the national day of France this week, July

More on GLP-1s: adherence, complications, impact on desire; nextgen weight management; and, Lisa Marie Presley’s tragic death Read More »

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow - not shrink - along with rising GLP-1 adoption.

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow – not shrink – along with rising GLP-1 adoption.

Hello everyone, I hope you are quite well on this beautiful weekend (at least, here in the US Northeast). Virtually everyone I know, including yours truly and family, are out & about enjoying it. In this edition of our twenty30 newsletter, we continue to see keen media attention on GLP-1s, helping facilitate public fascination and concurrent

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow – not shrink – along with rising GLP-1 adoption. Read More »

Bariatric surgery cuts cancer risk by 25%, obesity as a key public health threat in the US, only 9% of anti-obesity meds prescriptions are filled, and payer strategies for GLP-1 drugs.

Bariatric surgery cuts cancer risk by 25%, obesity as a key public health threat in the US, only 9% of anti-obesity meds prescriptions are filled, and payer strategies for GLP-1 drugs.

Hello everyone, I hope you are all enjoying a late summer weekend with family and friends. Key items this week have included news of a 25% reduction in the risk of cancer after bariatric surgery; that only 9% of prescriptions for obesity medicines were filled over 60 days; that obesity is believed to be one

Bariatric surgery cuts cancer risk by 25%, obesity as a key public health threat in the US, only 9% of anti-obesity meds prescriptions are filled, and payer strategies for GLP-1 drugs. Read More »

Scroll to Top
Skip to content